NASDAQ
3.86USD
-0.05 (-1.40%)
We have scored 6 news catalysts on Clene Inc. (CLNN) over the past 12 months. The biggest single-day move next to one of them came Dec 21, 2025, when CLNN closed +10.6%: “Clene (NASDAQ:CLNN) Major Shareholder Sells $444,695.22 in Stock”. Coverage across the window leans mixed (average ticker sentiment +0.03). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
50M
P/E
—
EPS
—
Beta
0.92
52W range
3.25-13.5
Day range
3.76–3.99
Open
3.90
Prev close
3.91
Volume
14.5K
Avg volume
98.9K
Dividend
0.00
IPO
2018-10-18
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Clene Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for CLNN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
